Brought to you by 
Series A brings in $30mm for Audentes
Jul 2013
Executive Summary
Audentes Therapeutics Inc., a start-up developing treatments for rare muscle diseases, raised $30mm in its Series A financing led by OrbiMed Advisors, which was joined by 5AM Ventures and Versant Ventures. Members of each venture firm will take board seats.
Deal Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings in $30mm for Audentes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice